How ARA-290 works
Experimental peptide studied for small-fiber nerve damage, with uncertain pain relief and safety.
Also called: Cibinetide, ARA 290, ARA290, pHBSP, pHSBP, Pyroglutamate helix B surface peptide.
Healing and repair peptides · EPO-derived peptide designed to activate the innate repair receptor.
ARA-290 copies a small part of erythropoietin. It was designed to reduce cell damage and support repair without increasing red blood cells. The proposed repair receptor contains EPOR and CD131, but its direct structure and binding remain debated.
- Proposed EPOR/CD131 innate repair receptor: Intended to trigger cell-protection and repair signals; direct receptor assembly is disputed.
- Blood-cell EPO receptor: Designed to avoid red-cell stimulation; short trials did not show a meaningful rise in hemoglobin.
Half-life: Reported as about 20 minutes in healthy volunteers after injection under the skin.
Related to ARA-290
- BPC-157: An experimental repair peptide with mostly animal evidence and a few small human reports.
- TB-500: A short piece of thymosin beta-4 with no proven repair benefit in humans.
- GHK-Cu: A copper-binding skin peptide with small topical studies and untested systemic injections.
- AHK-Cu: A copper peptide used in scalp serums, with laboratory findings and weak patent-only human data.
- Thymosin beta-4: A peptide studied for eye conditions and skin wounds; tendon-repair injections lack controlled human evidence.
- Ac-SDKP: An experimental repair peptide with old human studies, but no proven healing dose.
Sources
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding, FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Pyrogen and Endotoxins Testing: Questions and Answers, FDA · 2026
- Retraction Note: Delayed administration of pyroglutamate helix B surface peptide (pHBSP), a novel nonerythropoietic analog of erythropoietin, attenuates acute kidney injury., Patel NSA et al. · Molecular medicine (Cambridge, Mass.) · 2026
- Risks of buying peptide products online, Therapeutic Goods Administration · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- Think twice before injecting peptides bought online: unauthorized products can seriously harm you, Health Canada · Health Canada · 2026
- Supply unlicensed medicinal products (specials), MHRA · 2025
- ERS clinical practice guidelines on treatment of sarcoidosis., Baughman RP et al. · The European respiratory journal · 2021
- Health, Medical & Research Committee (HMRC) Meeting Minutes, World Anti-Doping Agency · 2017
- EU/3/13/1191 - orphan designation for treatment of sarcoidosis, European Medicines Agency · 2013
- Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances, FDA · FDA · 2000
- Case Report: Regenerative peptides for Inferior alveolar nerve injury: a narrative review with hypothesis-generating three clinical cases., Froum S et al. · Frontiers in oral health · 2026
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.